Premium
SPIO‐Au core–shell nanoparticles for promoting osteogenic differentiation of MC3T3‐E1 cells: Concentration‐dependence study
Author(s) -
Yuan Muzhaozi,
Wang Ya,
Qin YiXian
Publication year - 2017
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.36200
Subject(s) - biocompatibility , viability assay , zeta potential , chemistry , biophysics , nanoparticle , internalization , cytotoxicity , drug delivery , cell growth , nanotechnology , tissue engineering , cell , in vitro , biomedical engineering , materials science , biochemistry , medicine , biology , organic chemistry
This work aims to explore the concentration‐dependence of SPIO‐Au core–shell nanoscale particles (NPs) (17.3 ± 1.2 nm in diameter) on biocompatibility and osteogenic differentiation of preosteoblast MC3T3‐E1 cells. The stability of NPs was first investigated by UV–vis absorption spectra and zeta potential measurement. Then concentration effects of NPs (1–80 μg/mL) were evaluated on viability, morphology, proliferation, cellular uptake, and alkaline phosphate (ALP) activity levels. Results have shown strong stability and no acute toxicity (viability > 93%) or morphological difference at all concentration levels of NPs. The proliferation results indicated that the concentration of NPs below 40 μg/mL does not affect the cell proliferation for 7 days of incubation. Transmission electron microscopy images revealed the successful internalization of NPs into MC3T3‐E1 cells and the dose‐dependent accumulation of NPs inside the cytoplasm. The ALP level of MC3T3‐E1 cells was improved by 49% (of control) after treated with NPs at 10 μg/mL for 10 days, indicating their positive effect on early osteogenic differentiation. This study confirmed the excellent biocompatibility of SPIO‐Au NPs and their great potential for promoting osteogenic differentiation and promised the future application for these NPs in bone engineering including drug delivery, cell labeling, and activity tracking within scaffolds. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 3350–3359, 2017.